Landos Biopharma Inc (LABP)
$22.1501
+0.19
(+0.87%)▲
Insights on Landos Biopharma Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 325.6%
Performance
- $21.90$22.15$22.15
1.13%
Downside
Day's Volatility :1.13%
Upside
0.0%
- $2.50$22.15$22.15
88.71%
Downside
52 Weeks Volatility :88.71%
Upside
0.0%
Returns
| Period | Landos Biopharma Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 386.82% | 1.9% | 0.0% |
6 Months | 513.24% | 10.7% | 0.0% |
1 Year | 687.98% | 4.6% | -1.1% |
3 Years | -81.28% | 14.2% | -22.1% |
Highlights
Market Capitalization | 68.5M |
Book Value | $10.2 |
Earnings Per Share (EPS) | -3.5 |
Wall Street Target Price | 12.71 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -34.11% |
Return On Equity TTM | -61.86% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 18.0M |
EBITDA | -22.2M |
Diluted Eps TTM | -3.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.19 |
EPS Estimate Next Year | -1.68 |
EPS Estimate Current Quarter | -0.91 |
EPS Estimate Next Quarter | -0.88 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 42.62%
Technicals Summary
Sell
Neutral
Buy
Landos Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Landos Biopharma Inc | 3.51% | 513.24% | 687.98% | -81.28% | -81.54% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Landos Biopharma Inc | NA | NA | NA | -2.19 | -0.62 | -0.34 | NA | 10.2 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Landos Biopharma Inc | Hold | $68.5M | -81.54% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
Perceptive Advisors LLC
47.71%Macquarie Group Ltd
0.47%Geode Capital Management, LLC
0.40%Renaissance Technologies Corp
0.36%
Corporate Announcements
Landos Biopharma Inc Earnings
Landos Biopharma Inc’s price-to-earnings ratio stands at None
Read More
Company Information
there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.
Organization | Landos Biopharma Inc |
Employees | 19 |
CEO | Mr. Gregory Oakes |
Industry | Healthcare |
